This is the authors' abstract. We don't add key points for this paper.
Fluorescent probe-based TR-FRET biochemical assays are widely utilized in characterizing ligands’ binding activities, whereas fluorescent probe-based NanoBRET target engagement (TE) assays are gaining popularity in characterizing ligands for their cellular activities. Compared to TR-FRET assays, few fluorophores were explored in NanoBRET assays. In this study, we investigated five (+)-JQ1-based fluorescent probes with BODIPY FL, FITC, TAMRA, NanoBRET 590 and Cy5 as the corresponding fluorophores and tested them as the probes in both TR-FRET and NanoBRET assays with BRD4 as the target. All five probes functioned as suitable TR-FRET probes with the BODIPY FL-(+)-JQ1 having the highest sensitivity and affinity. However, only BODIPY FL-(+)-JQ1 and NanoBRET 590-(+)-JQ1 were compatible with live-cell NanoBRET TE assays, with the NanoBRET 590-(+)-JQ1 demonstrating superior sensitivity, but the other 3 probes: (+)-JQ1-FITC, TAMRA-(+)-JQ1 and Cy5-(+)-JQ1, were functional only under digitonin-permeabilized conditions. By testing a panel of BRD4 ligands, we found that the combination of TR-FRET binding and NanoBRET TE assays reveal not only ligands’ binding activities but also their cellular permeability.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: